Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Wertheim cung cấp cho các bạn kiến thức về ngành y đề tài: Meeting the challenges of drug discovery: a multidisciplinary re-evaluation of current practices. | Meeting report Meeting the challenges of drug discovery a multidisciplinary re-evaluation of current practices Stephen K Burley and Frances Park Address SGX Pharmaceuticals Inc. 10505 Roselle Street San Diego CA 92121 USA. Correspondence Stephen K Burley. E-mail sburley@ Published 24 June 2005 Genome Biology 2005 6 330 doi gb-2005-6-7-330 The electronic version of this article is the complete one and can be found online at http 2005 6 7 330 2005 BioMed Central Ltd A report on the Keystone Symposium Meeting the Challenges of Drug Discovery Vancouver Canada 15-19 January 2005. With the cost of bringing a new therapeutic agent to the market now estimated at around US billion and the disappointing pace of approvals of new therapeutics the pharmaceutical and biotechnology industries are under increasing pressure to improve the efficiency and economics of drug discovery and development. A Keystone Symposium in January on the challenges of drug discovery brought together an eclectic group of innovators. An ambitious meeting program encompassed target validation lead-identification strategies novel screening approaches early detection of toxicity more predictive animal models new biomarkers molecular profiling and new biological agents. Leslie Brown Pharmacopeia Princeton USA in his keynote lecture gave an entertaining and wide-ranging analysis of the myriad financial and technical challenges facing the pharmaceutical and biotechnology industries. His message can be summed up as use the right technology to find the right drug modulating the right target in the right patient . We learned over the next four days that such advice is easy to give but more difficult to heed. Using the right technology Several complementary strategies for speeding up the drugdiscovery process were presented. David Burns Abbott Laboratories Abbott Park USA described how he and colleagues are using high-throughput screening to accelerate the initial .
